Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience

Απλή σελίδα τεκμηρίου
dc.contributor.authorPectasides, D.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorEfstathiou, E.en
dc.contributor.authorSalamalekis, E.en
dc.contributor.authorFarmakis, D.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorDimopoulos, M. A.en
dc.date.accessioned2015-11-24T19:37:23Z
dc.date.available2015-11-24T19:37:23Z
dc.identifier.issn0090-8258-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24023
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma, Mucinous/*drug therapy/pathology/surgeryen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCarboplatin/administration & dosage/*therapeutic useen
dc.subjectCisplatin/administration & dosage/*therapeutic useen
dc.subjectCombined Modality Therapyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectOvarian Neoplasms/*drug therapy/pathology/surgeryen
dc.subjectPaclitaxel/administration & dosageen
dc.subjectRetrospective Studiesen
dc.subjectSurvival Rateen
dc.subjectTreatment Outcomeen
dc.titleAdvanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experienceen
heal.abstractOBJECTIVE: Mucinous epithelial ovarian cancer (mEOC) representing about 10% of all EOC are known to be possibly resistant to platinum-based chemotherapy and bear a poorer prognosis with respect to other subtypes of EOC. This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stages III and IV mEOC and serous EOC (sEOC). METHODS: A retrospective analysis was performed in 47 patients with advanced stage of mEOC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 6/7/1983 and 25/2/2003. The outcome was compared to that of 94 patients with sEOC treated with the same protocols during the same study period (ratio mucinous: serous 1:2). RESULTS: One hundred forty-one patients (47 stages III and IV mEOC, 94 stages III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for mEOC was 38.5% (complete remission 18%) (95% CI 23.4-55.4%) and 70% (complete remission 47%) (95% CI 58.5-80.3%) for sEOC (P = 0.001). After a median follow-up of 77.8 months, median survival and time to tumor progression (TTP) were not significantly different between the two groups (33.2 months [95% CI 23.3-43.1 months] vs. 38.0 months [95% CI 26.8-49.2 months], P = 0.46, 11.8 months [95% CI 7.2-16.4 months] vs. 20.0 months [95% CI 15.7-24.2 months], P = 0.18, respectively). CONCLUSION: Patients with mEOC have significantly lower response to first-line platinum-based chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in inferior TTP or survival. Our data indicate that a new strategy for chemotherapy in mEOC should be adopted, one that focuses on new agents without cross-resistance to platinum agents.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.ygyno.2004.12.056-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15863142-
heal.identifier.secondaryhttp://ac.els-cdn.com/S009082580500017X/1-s2.0-S009082580500017X-main.pdf?_tid=ab671e543367e45f7122b017e1d8e236&acdnat=1333703539_fe6d358290794b86caec87e681213b26-
heal.journalNameGynecol Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ